Full Prescribing Information
Important Safety Information
Patient Site
  • ABOUT LYNKUET
  • CLINICAL
 DATA
    • SAFETY
  • RESOURCES

For the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause1


PROMIS SD SF 8b Data 

PROMIS SD SF 8b data: Changes in patient-reported sleep disturbance

Moderate to severe VMS can be associated with sleep disturbances2

REVIEW OASIS 1 &

OASIS 2 STUDY DESIGN

The mean change in the
P
atient-
R
eported
O
utcomes
M
easurement
I
nformation
S
ystem
S
leep
D
isturbance-
S
hort
F
orm
8b
(
PROMIS SD SF 8b
) total T-score from baseline to Week 12 is a key secondary endpoint in OASIS 1 and OASIS 2.
3

PROMIS SD SF 8b assesses the self-reported perception of sleep disturbance over the past 7 days3

Includes 8 items3*:

  • Restless sleep
  • Satisfaction with sleep
  • Refreshing sleep
  • Difficulties falling asleep
  • Staying asleep
  • Getting to sleep
  • Amount of sleep
  • Sleep quality

*Items were scored on a 5-point Likert scale, and the 8 single item scores were summed to yield total raw scores (range, 8-40), which were converted to total T-scores for analysis of the key secondary endpoint (range, 28.9-76.5).3

Higher scores indicate more disturbed sleep.3

Mean change in PROMIS SD SF 8b total T-score from baseline to Week 12

Graph showing mean change in PROMIS SD SF 8b total T-score from baseline to Week 12 in OASIS 1
Graph showing mean change in PROMIS SD SF 8b total T-score from baseline to Week 12 in OASIS 1
SEE SAFETY DATA
Data Over Time
Safety